Compare Abbott Laboratories (ABT) vs Pfizer Inc (PFE) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs Pfizer Inc — how do they compare? Abbott Laboratories trades at $95.24 (market cap $166.94B), while Pfizer Inc trades at $24.24 (market cap $137.19B). The key difference: Abbott Laboratories is the larger of the two by market cap, and Pfizer Inc pays the higher dividend (7.15%). Which is the better fit depends on your goals.
| ABT | PFE | |
|---|---|---|
Market Cap | $166.94B | $137.19B |
Sector | Health | Health |
52-Week High | $136.62 | $28.56 |
52-Week Low | $82.57 | $23.29 |
Enterprise Value | $193.69B | $187.84B |
Dividend Yield | 2.63% | 7.15% |
Volume | — | 29,869,932 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
Pfizer (PFE) trades at $23.72, down 2.47% on the day, with a bearish technical signal from moving averages but recent earnings beats. The stock has a P/E of 18.11 and net income margin of 11.83%, supported by strong cash flow from operations of $11.70B in 2025. Recent news highlights pipeline progress in obesity and oncology, with dividends of $0.43 paid semi-annually.
The outlook is mixed: analyst consensus is a 'Hold' with a $27.63 price target, implying potential upside, but risks include patent cliffs and competitive pressures. Revenue has declined from pandemic peaks, yet cost controls sustain profitability. Investors may find value if pipeline catalysts materialize, though near-term volatility persists.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →
